Anti-PD-L1 Antibody (1N521)
Cat# NB-64-125056-20uL
Size : 20uL
Brand : Neo Biotech
Contact local distributor :
Phone : +1 850 650 7790
Remove All
Anti-PD-L1 Antibody (1N521)
(Synonyms: Pdl1, Pdcd1lg1, Pdcd1l1, CD274 molecule, B7h1, A530045L16Rik) Copy Product InfoSynonyms: Pdl1, Pdcd1lg1, Pdcd1l1, CD274 molecule, B7h1, A530045L16Rik
Catalog No. TMAY-03025 Copy Product Info
Anti-PD-L1 Antibody (1N521) is a Rabbit antibody targeting PD-L1. Anti-PD-L1 Antibody (1N521) can be used in ELISA.
For research use only—not for human use. No sales to individuals. Use as intended only.
Product Information
Bioactivity
Related Conjugates and Formulations
Antigen Details
Stability & Storage
| Description | Anti-PD-L1 Antibody (1N521) is a Rabbit antibody targeting PD-L1. Anti-PD-L1 Antibody (1N521) can be used in ELISA. |
| Synonyms | Pdl1, Pdcd1lg1, Pdcd1l1, CD274 molecule, B7h1, A530045L16Rik |
| Ig Type | Rabbit IgG |
| Clone | 1N521 |
| Reactivity | Mouse |
| Specificity | Mouse PD-L1/B7-H1 |
| Application | ELISA |
| Recommended Dose | ELISA: 1:5000-1:10000 |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse PD-L1/B7-H1/CD274 (rM PD-L1/B7-H1/CD274; TMPY-01155; NP_068693.1; Met1-Thr238). |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy |
| Conjucates | Unconjugated |
| Immunogen | Recombinant Protein: Mouse PD-L1/B7-H1/CD274 Protein (TMPY-01155) |
| Antigen Species | Mouse |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |
Calculator
Preview
Related Tags:
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote